Actively Recruiting
Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
Led by Arrowhead Pharmaceuticals · Updated on 2026-04-13
36
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
CONDITIONS
Official Title
Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinically stable, mild atopic asthma with FEV1 70% predicted
- Confirmed allergy by positive skin prick test at screening
- Willing and able to perform lung function tests and study procedures
- Participants of childbearing potential must agree to use highly-effective contraception plus condom during the study and for at least 90 days after last dose
You will not qualify if you...
- Diagnosis of any significant lung disease other than asthma
- Use of corticosteroids, immunosuppressives, or anti-inflammatory drugs that affect inhaled challenges or inflammation
- Chronic use of other medications for allergic asthma
- History or current condition that prevents methacholine challenge
- Additional criteria may apply as per protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Research Site 1
Vancouver, British Columbia, Canada
Actively Recruiting
Research Team
M
Medical Monitor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here